Introduction
The subcutaneous (SC) formulation of the infliximab (IFX) biosimilar CT-P13 is increasingly used in inflammatory bowel disease (IBD). A direct comparison between patients switched from intravenous (IV) IFX to SC CT-P13 and those who remained on IV IFX may provide valuable insights for clinical decision-making.
Aims & Methods
CISI is a retrospective, single-center, observational study conducted at the IBD Unit of “Villa Sofia-Cervello” Hospital, Palermo, Italy. Consecutive adult patients with Crohn’s disease (CD) or ulcerative colitis (UC) in stable, steroid-free clinical remission (Harvey-Bradshaw Index <5 for CD or partial Mayo score <2 for UC, without steroid use for ≥4 months) while on maintenance IV IFX (5 mg/kg every 8 weeks) were included. Two arms were compared. Arm 1: patients in stable, steroid-free remission who were switched from IV IFX to SC CT-P13; Arm 2: patients in stable, steroid-free remission who continued IV IFX. A propensity score-weighted analysis using inverse probability of treatment weighting (IPTW) with stabilized weights was applied to reduce selection bias. The primary endpoint was time to treatment failure. Secondary endpoints included the incidence rate (IR) of adverse events (AEs) and the clinical activity at 6, 12, and 24 months.
Results
Overall, 251 patients were included (CD: 53.8%, UC: 46.2%): 134 remained on IV IFX and 117 were switched to SC CT-P13. Mean follow-up was 24.7 ± 29.8 months for IV IFX and 20.9 ± 14.9 months for SC CT-P13 (p=0.41). Time to treatment failure did not differ significantly between groups (log-rank p=0.10 – figure 1). In the multivariable Cox model, female sex was independently associated with higher risk of treatment failure (HR 2.59; 95% CI 1.66–4.04; p<0.001). A significant time-dependent effect was detected for the SC CT-P13 (p=0.005). During the first months after switching, patients on SC CT-P13 showed a higher probability of treatment discontinuation compared with those maintained on IV therapy. However, this excess risk progressively decreased and crossed unity around month 8, after which the likelihood of persistence became higher for SC CT-P13. The AE IR was 6.16 (95% CI 3.59–9.87) per 100 person-years for IV IFX and 4.42 (95% CI 2.02–8.39) for SC CT-P13. The IPTW-adjusted IR ratio (SC/IV) was 0.95 (95% CI 0.38–2.42; p=0.92). No significant differences between the two arms were observed in HBI, partial Mayo score, or CRP levels at 6, 12, or 24 months.
Conclusion
Switching from IV IFX to SC CT-P13 demonstrated comparable persistence, safety, and disease control to continued IV therapy in IBD patients with stable steroid-free remission.
Disclosure
Disclosures: FSM served as an advisory board member and/or received lecture grants from AbbVie, Alfasigma, Ferring, Galapagos, Giuliani, Janssen, Lilly, Lionhealth s.r.l., Pfizer, Takeda Pharmaceuticals, Sandoz. SR served as an advisory board member or received lecture grants from AbbVie, Johnson and Johnson, Pfizer, Alfasigma, Takeda, Eli Lilly. AO served as an advisory board member for AbbVie, Alfasigma, Biogen, Celltrion, Eli-Lilly, Galapagos, Giuliani, Lionealth s.r.l., MSD, Janssen, Pfizer, and Takeda Pharmaceuticals and received lecture grants from AbbVie, Alfasigma, Celltrion, Fresenius- Kabi, Galapagos, MSD, Ferring, Giuliani, Sofar, Chiesi, Janssen, Eli-Lilly, Pfizer, Sandoz, and Takeda Pharmaceuticals.
Funding: This is an investigator-initiated study (IIS) unconditionally funded by Celltrion Healthcare Italy S.r.l